ST-920

BIOLOGICAL4 trials

Sponsors

Sangamo Therapeutics Inc., Sangamo Therapeutics

Conditions

Fabry DiseaseFabry Disease (X-linked lysosomal storage disease).Fabry Disease, Cardiac Variant

Phase 1

Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)

CompletedNCT04046224

Sangamo TherapeuticsFabry Disease

Start: 2019-07-23End: 2025-04-10Updated: 2026-04-14

A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects with Fabry Disease.

CompletedCTIS2024-512695-34-00

Sangamo Therapeutics Inc.Fabry Disease (X-linked lysosomal storage disease).

Start: 2022-06-28End: 2025-03-19Target: 8Updated: 2024-07-26

Phase 2

Long-Term Follow-up of Fabry Disease Subjects who were Treated with ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy

Active, not recruitingCTIS2024-512700-18-00

Sangamo Therapeutics Inc.Fabry Disease (X-linked lysosomal storage disease).

Start: 2025-04-03Target: 1Updated: 2025-06-18

Unknown Phase

Long-Term Follow-up of Subjects Who Were Treated With ST-920

Active, not recruitingNCT05039866

Sangamo TherapeuticsFabry Disease, Fabry Disease, Cardiac Variant

Start: 2021-08-16End: 2039-03-01Updated: 2026-08-20